

Vasodilator and Exercise Study for DMD (VASO-REx)

NCT06290713

Status	RECRUITING
Phase	Phase 2
Sponsor	University of Florida
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (4)

- Diagnosis of DMD confirmed by genetic report
- Minimum entry age of 6.0 years old
- Ambulatory
- On stable glucocorticoid regimen (for $>$ 3 months)

Exclusion (6)

- Contraindication to a Magnetic resonance Imaging examination (e.g. severe claustrophobia, magnetic implants, unable/unwilling to perform test)
- Presence of unstable medical problems, including severe cardiomyopathy, left ventricular ejection fraction $<$ 45%, cardiac conduction abnormalities as evidenced on ECG, uncontrolled seizure disorder, uncontrolled hypo or hypertension
- Presence of a secondary condition that impacts muscle function or muscle metabolism (e.g., myasthenia gravis, endocrine disorder, mitochondrial disease)
- Presence of a secondary condition leading to developmental delay or impaired motor control (e.g., cerebral palsy) or previous history of unprovoked rhabdomyolysis
- Contraindications to phosphodiesterase 5 inhibitors (use of nitrates, alpha-adrenergic blockers, other phosphodiesterase 5 inhibitors) or other medications known to modulate blood flow or muscle metabolism

... and 1 more (see full listing online)

Locations (1 total)

University of Florida Clinical and Translational Research Building, Gainesville, Florida, United States

<https://clinicaltrials.gov/study/NCT06290713>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).